{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:26:47Z","timestamp":1787030807571,"version":"build-2736575974"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motor neuron degeneration, leading to muscle weakness, atrophy, and ultimately respiratory failure. Previous research has highlighted the roles of neurotrophic factors and inflammatory responses in ALS pathogenesis; however, their interplay remains poorly understood. This exploratory study aims to elucidate the expression characteristics and correlations of fibroblast growth factor 2 (FGF2) and peripheral blood inflammatory indicators (PBIIs) such as derived neutrophil-to-lymphocyte ratio (dNLR) and systemic inflammatory response index (SIRI) in ALS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a prospective case\u2013control study, involving ALS patients meeting Gold Coast diagnostic criteria and age- and sex-matched healthy controls (HCs). Serum FGF2 levels were measured using enzyme-linked immunosorbent assay (ELISA), and PBIIs were assessed through routine blood analysis. Statistical analysis was conducted mainly using intergroup comparison, correlation analysis, and multivariate linear regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The results showed significantly elevated levels of FGF2 and PBIIs in ALS patients compared to HCs, with strong correlations between FGF2, PBIIs, clinical staging, and disease progression rates. In multivariate linear regression analysis, PBIIs, especially SIRI, were significantly associated with disease severity and early disease progression. While serum FGF2 and FGF2 to dNLR ratio demonstrated potential as an auxiliary biomarker for later-stage disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings provide new insights into the molecular mechanisms underlying ALS and suggest practical diagnostic and prognostic tools, reinforcing the importance of targeting neurotrophic and inflammatory pathways in ALS management. This study holds significant promise for advancing both clinical practice and future research endeavors in the field.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1859903","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:29:07Z","timestamp":1787027347000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Increased serum fibroblast growth factor 2 levels, altered peripheral blood inflammatory indicators and their ratios in amyotrophic lateral sclerosis: a clinical exploratory study"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaoting","family":"Niu","sequence":"first","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanjie","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyi","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"101684","DOI":"10.1016\/j.lanwpc.2025.101684","article-title":"Pan-Asian consortium for treatment and research in ALS (PACTALS) guidelines for management of amyotrophic lateral sclerosis","volume":"62","author":"Vucic","year":"2025","journal-title":"Lancet Reg Health West Pac"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3390\/cells13110888","article-title":"Updates on disease mechanisms and therapeutics for amyotrophic lateral sclerosis","volume":"13","author":"Nguyen","year":"2024","journal-title":"Cells"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12035-024-04269-3","article-title":"The current potential pathogenesis of amyotrophic lateral sclerosis","volume":"62","author":"Jiang","year":"2025","journal-title":"Mol Neurobiol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1515\/revneuro-2024-0037","article-title":"Current potential diagnostic biomarkers of amyotrophic lateral sclerosis","volume":"35","author":"Xu","year":"2024","journal-title":"Rev Neurosci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1608853","DOI":"10.3389\/fmolb.2025.1608853","article-title":"Emerging biomarkers in amyotrophic lateral sclerosis: from pathogenesis to clinical applications","volume":"12","author":"Anjum","year":"2025","journal-title":"Front Mol Biosci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12883-022-02730-1","article-title":"Serum biomarkers of neuroinflammation and blood-brain barrier leakage in amyotrophic lateral sclerosis","volume":"22","author":"Cao","year":"2022","journal-title":"BMC Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1605822","DOI":"10.3389\/fneur.2025.1605822","article-title":"Unlocking amyotrophic lateral sclerosis: the role of adiponectin in inflammation and disease progression","volume":"16","author":"Tian","year":"2025","journal-title":"Front Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"9299","DOI":"10.3390\/ijms23169299","article-title":"Biomarkers in neurodegenerative diseases: proteomics spotlight on ALS and Parkinson's disease","volume":"23","author":"Raghunathan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2174\/0109298665391103250825102319","article-title":"Precision enzyme: targeted drug discovery in neurodegenerative disorders","volume":"32","author":"Paul","year":"2025","journal-title":"Protein Pept Lett"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e18761429261684","DOI":"10.2174\/0118761429261684231002062505","article-title":"Targeting FGFR3 is a useful therapeutic strategy for rheumatoid arthritis treatment","volume":"17","author":"Yu","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1089\/brain.2020.0741","article-title":"In amyotrophic lateral sclerosis blood cytokines are altered, but do not correlate with changes in brain topology","volume":"10","author":"Polverino","year":"2020","journal-title":"Brain Connect"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"114902","DOI":"10.1016\/j.intimp.2025.114902","article-title":"cGAS-STING and neurodegenerative diseases: a molecular crosstalk and therapeutic perspective","volume":"159","author":"Dhapola","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.clinph.2020.04.005","article-title":"A proposal for new diagnostic criteria for ALS","volume":"131","author":"Shefner","year":"2020","journal-title":"Clin Neurophysiol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1498757","DOI":"10.3389\/fnut.2025.1498757","article-title":"The association between eight complete blood count-derived inflammatory markers and muscle health","volume":"12","author":"Zhang","year":"2025","journal-title":"Front Nutr"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1097\/00001756-200310060-00022","article-title":"Increased serum and cerebrospinal fluid FGF-2 levels in amyotrophic lateral sclerosis","volume":"14","author":"Johansson","year":"2003","journal-title":"Neuroreport"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/ane.12381","article-title":"bFGF in the CSF and serum of sALS patients","volume":"132","author":"Gong","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"ref17","first-page":"7395","article-title":"Characterizing the multiple roles of FGF-2 in SOD1(G93A) ALS mice in vivo and in vitro","volume-title":"J Cell Physiol","author":"Kefalakes","year":"2019"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1007\/s12035-021-02367-0","article-title":"Fibroblast growth factor Signalling in the diseased nervous system","volume":"58","author":"Klimaschewski","year":"2021","journal-title":"Mol Neurobiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.cytogfr.2020.05.004","article-title":"Intracellular partners of fibroblast growth factors 1 and 2 - implications for functions","volume":"57","author":"Sluzalska","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1663276","DOI":"10.3389\/fnins.2025.1663276","article-title":"Plasma FGF2 and YAP1 as novel biomarkers for MCI in the elderly: analysis via bioinformatics and clinical study","volume":"19","author":"Zhao","year":"2025","journal-title":"Front Neurosci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"8858","DOI":"10.62347\/FGWO4419","article-title":"Nomogram for predicting postpartum pelvic floor dysfunction based on ultrasound and serum biomarkers FGF2 and HBP","volume":"17","author":"Sun","year":"2025","journal-title":"Am J Transl Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"19796","DOI":"10.1038\/s41598-024-67165-9","article-title":"Inflammatory signature in amyotrophic lateral sclerosis predicting disease progression","volume":"14","author":"Femiano","year":"2024","journal-title":"Sci Rep"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"578683","DOI":"10.1016\/j.jneuroim.2025.57868","article-title":"Predictors from systemic and neuro-inflammation in amyotrophic lateral sclerosis: a monocentric experience","volume":"406","author":"Martinelli","year":"2025","journal-title":"J Neuroimmunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1002\/jcsm.13618","article-title":"Prognostic value of systemic inflammation, nutritional status and sarcopenia in patients with amyotrophic lateral sclerosis","volume":"15","author":"Zhu","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1552949","DOI":"10.3389\/fnins.2025.1552949","article-title":"The systemic inflammation markers as potential predictors of disease progression and survival time in amyotrophic lateral sclerosis","volume":"19","author":"Hong","year":"2025","journal-title":"Front Neurosci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.3390\/ijms23073636","article-title":"Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases","volume":"23","author":"Buonacera","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12872-024-03768-4","article-title":"Serum fibroblast growth factor-2 levels complement vital biomarkers for diagnosing heart failure","volume":"24","author":"Yu","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jad.2020.12.055","article-title":"Fibroblast growth factor 2 implicated in childhood anxiety and depression symptoms","volume":"282","author":"Lebowitz","year":"2021","journal-title":"J Affect Disord"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"151181","DOI":"10.1016\/j.bbrc.2024.151181","article-title":"Neuroprotective effects of activated fibroblast growth factor receptor 1 via the suppression of p53 accumulation against poly-PR-mediated toxicity","volume":"743","author":"Taisei","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3390\/cells10040884","article-title":"FGF\/FGFR pathways in multiple sclerosis and in its disease models","volume":"10","author":"Rajendran","year":"2021","journal-title":"Cells"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1859903\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:29:10Z","timestamp":1787027350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1859903\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":30,"alternative-id":["10.3389\/fneur.2026.1859903"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1859903","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1859903"}}